




PHARMACEUTICAL 2019

Astria Therapeutics Inc.
Rank 119 of 363





RealRate

PHARMACEUTICAL 2019

Astria Therapeutics Inc.
Rank 119 of 363



The relative strengths and weaknesses of Astria Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Astria Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 116% points. The greatest weakness of Astria Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 46% points.

The company's Economic Capital Ratio, given in the ranking table, is 158%, being 121% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	38,915
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,171
Liabilities, Non-Current	47
Other Assets	198
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	9.0
Other Net Income	501
Other Revenues	0
Property and Equipment	56
Research and Development	17,042
Selling, General and Administrative Expense	9,329

Output Variable	Value in 1000 USD
Assets	39,169
Liabilities	4,227
Expenses	26,371
Revenues	0
Stockholders Equity	34,942
Net Income	-25,870
Comprehensive Net Income	-25,870
Economic Capital Ratio	158%